NO965590L - Polynukleotidvaksine for papillomvirus - Google Patents
Polynukleotidvaksine for papillomvirusInfo
- Publication number
- NO965590L NO965590L NO965590A NO965590A NO965590L NO 965590 L NO965590 L NO 965590L NO 965590 A NO965590 A NO 965590A NO 965590 A NO965590 A NO 965590A NO 965590 L NO965590 L NO 965590L
- Authority
- NO
- Norway
- Prior art keywords
- dna
- crpv
- hpv
- gene
- papilloma virus
- Prior art date
Links
- 241001631646 Papillomaviridae Species 0.000 title claims abstract description 47
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 102
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 241001465754 Metazoa Species 0.000 claims abstract description 24
- 241000701806 Human papillomavirus Species 0.000 claims description 34
- 229960005486 vaccine Drugs 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 101900163635 Cottontail rabbit papillomavirus Major capsid protein L1 Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 2
- 230000005026 transcription initiation Effects 0.000 claims description 2
- 101900043895 Cottontail rabbit papillomavirus Minor capsid protein L2 Proteins 0.000 claims 1
- 101900118757 Cottontail rabbit papillomavirus Probable protein E5 Proteins 0.000 claims 1
- 101900175244 Cottontail rabbit papillomavirus Protein E6 Proteins 0.000 claims 1
- 101900175240 Cottontail rabbit papillomavirus Protein E7 Proteins 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 6
- 230000000069 prophylactic effect Effects 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 72
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 33
- 241000283973 Oryctolagus cuniculus Species 0.000 description 31
- 239000013598 vector Substances 0.000 description 29
- 241000700605 Viruses Species 0.000 description 22
- 239000012634 fragment Substances 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 17
- 230000003472 neutralizing effect Effects 0.000 description 16
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 208000000260 Warts Diseases 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 201000010153 skin papilloma Diseases 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108010067390 Viral Proteins Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 206010059313 Anogenital warts Diseases 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 208000009608 Papillomavirus Infections Diseases 0.000 description 6
- 108010006025 bovine growth hormone Proteins 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229960002566 papillomavirus vaccine Drugs 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000742340 Human papillomavirus type 16 Minor capsid protein L2 Proteins 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 101710195240 Cysteine-rich venom protein Proteins 0.000 description 1
- 101710167080 Cysteine-rich venom protein 2 Proteins 0.000 description 1
- 101710190922 Cysteine-rich venom protein pseudechetoxin-like Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007842 Fibroepithelial Neoplasms Diseases 0.000 description 1
- 241000201835 Froelichia floridana Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 101150027802 L2 gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710157639 Minor capsid protein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 101710123658 Venom allergen 3 Proteins 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 101710178543 Venom allergen 5.01 Proteins 0.000 description 1
- 101710178552 Venom allergen 5.02 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000012999 benign epithelial neoplasm Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000005877 long-lasting humoral immunity Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26842494A | 1994-06-30 | 1994-06-30 | |
| PCT/US1995/006915 WO1996000583A1 (en) | 1994-06-30 | 1995-06-01 | Polynucleotide vaccine for papillomavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO965590D0 NO965590D0 (no) | 1996-12-27 |
| NO965590L true NO965590L (no) | 1997-02-28 |
Family
ID=23022939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO965590A NO965590L (no) | 1994-06-30 | 1996-12-27 | Polynukleotidvaksine for papillomvirus |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5866553A (ja) |
| EP (1) | EP0768893B1 (ja) |
| JP (1) | JPH10501987A (ja) |
| CN (1) | CN1156966A (ja) |
| AT (1) | ATE233101T1 (ja) |
| AU (1) | AU701973B2 (ja) |
| CA (1) | CA2193365C (ja) |
| CZ (1) | CZ375296A3 (ja) |
| DE (1) | DE69529748T2 (ja) |
| ES (1) | ES2191052T3 (ja) |
| FI (1) | FI965224A (ja) |
| HU (1) | HU220747B1 (ja) |
| IL (1) | IL113817A (ja) |
| MX (1) | MX9700229A (ja) |
| NO (1) | NO965590L (ja) |
| NZ (1) | NZ288045A (ja) |
| PL (1) | PL180639B1 (ja) |
| SK (1) | SK164196A3 (ja) |
| WO (1) | WO1996000583A1 (ja) |
| ZA (1) | ZA954641B (ja) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6995008B1 (en) * | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
| US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| FR2751879B1 (fr) * | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
| DE19631357A1 (de) * | 1996-08-02 | 1998-02-05 | Deutsches Krebsforsch | Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
| US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| EP1017283B1 (en) * | 1997-02-14 | 2004-12-15 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
| US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| US20040258703A1 (en) * | 1997-11-14 | 2004-12-23 | The Government Of The Us, As Represented By The Secretary Of The Army | Skin-active adjuvants for transcutaneous immunization |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| EP1071377A1 (en) * | 1998-04-14 | 2001-01-31 | Merck & Co., Inc. | Needleless administration of polynucleotide formulations |
| NZ510488A (en) * | 1998-09-04 | 2003-07-25 | Aventis Pasteur | Immunotherapy for HPV DNA-positive cervical cancers with DNA constructs for the administration of HPV antigens to provide an immune response in a host |
| US20020054914A1 (en) * | 1999-02-03 | 2002-05-09 | Tulin Morcol | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein |
| US20040258763A1 (en) * | 1999-02-03 | 2004-12-23 | Bell Steve J.D. | Methods of manufacture and use of calcium phosphate particles containing allergens |
| US6355271B1 (en) * | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| ES2308069T3 (es) * | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
| AU4188100A (en) * | 1999-04-08 | 2000-11-14 | Gregory M. Glenn | Dry formulation for transcutaneous immunization |
| ATE284898T1 (de) * | 1999-08-25 | 2005-01-15 | Merck & Co Inc | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| KR100366608B1 (ko) * | 2000-02-15 | 2003-01-09 | 마스터진(주) | 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신 |
| US20020044948A1 (en) * | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| SE0002498D0 (sv) * | 2000-07-03 | 2000-07-03 | Stefan Schwartz | Papillomavirus vaccine |
| KR20020005332A (ko) * | 2000-07-10 | 2002-01-17 | 정상훈 | 탈모증 치료용 키트 |
| PT1372708E (pt) * | 2001-02-13 | 2008-09-29 | Us Gov Sec Army | Vacina para imunização transcutânea |
| US20040241181A1 (en) * | 2001-06-22 | 2004-12-02 | Ertl Hildeghund C. J. | Methods of inducing a cytotoxic immune response and recormbinant simian adenovirus compositions useful therein |
| DE10137102A1 (de) * | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
| US20030185892A1 (en) * | 2001-08-17 | 2003-10-02 | Bell Steve J. D. | Intraocular delivery compositions and methods |
| US20030228327A1 (en) * | 2001-11-05 | 2003-12-11 | Lasher Alfred W. | DNA-based plasmid formulations and vaccines and prophylactics containing the same |
| ES2618309T3 (es) * | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Partículas de replicón de alfavirus multi-antigénico y métodos |
| AU2005219372A1 (en) * | 2004-02-13 | 2005-09-15 | Safeway Investments Ltd. | Therapeutic calcium phosphate particles and methods of making and using same |
| US20090041812A1 (en) * | 2004-11-01 | 2009-02-12 | Bell Steve J D | Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use |
| AU2006210792B2 (en) * | 2005-02-01 | 2012-07-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies |
| CN101570571B (zh) | 2007-04-29 | 2012-07-11 | 北京万泰生物药业股份有限公司 | 截短的人乳头瘤病毒18型l1蛋白 |
| BRPI0811016B1 (pt) * | 2007-04-29 | 2021-09-21 | Xiamen Innovax Biotech Co., Ltd. | Proteína li truncada do papiloma vírus humano tipo 16 |
| DK2154149T3 (da) * | 2007-05-29 | 2019-10-14 | Univ Xiamen | En trunkeret l1-protein af human papillomavirus 6 |
| KR20150128900A (ko) * | 2013-03-15 | 2015-11-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항원 및 어쥬번트로서 인터류킨-23을 갖는 백신 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
| ATE79138T1 (de) * | 1985-04-04 | 1992-08-15 | Univ Georgetown | Typenspezifische papillomavirus-dns-sequenzen und peptide. |
| US4777239A (en) * | 1986-07-10 | 1988-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic peptides of human papilloma virus |
| WO1990011092A1 (en) * | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
| ATE332973T1 (de) * | 1991-07-19 | 2006-08-15 | Univ Queensland | Polynukleotidabschnitt des hpv16-genoms |
| US5376542A (en) * | 1992-04-27 | 1994-12-27 | Georgetown University | Method for producing immortalized cell lines using human papilluma virus genes |
| EP0586076B1 (en) * | 1992-08-07 | 2003-06-25 | Wyeth | Recombinant adenovirus vaccines |
| US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
-
1995
- 1995-05-22 IL IL11381795A patent/IL113817A/en not_active IP Right Cessation
- 1995-06-01 CA CA002193365A patent/CA2193365C/en not_active Expired - Fee Related
- 1995-06-01 SK SK1641-96A patent/SK164196A3/sk unknown
- 1995-06-01 DE DE69529748T patent/DE69529748T2/de not_active Expired - Fee Related
- 1995-06-01 US US08/750,810 patent/US5866553A/en not_active Expired - Fee Related
- 1995-06-01 AU AU26945/95A patent/AU701973B2/en not_active Ceased
- 1995-06-01 ES ES95922160T patent/ES2191052T3/es not_active Expired - Lifetime
- 1995-06-01 CZ CZ963752A patent/CZ375296A3/cs unknown
- 1995-06-01 MX MX9700229A patent/MX9700229A/es unknown
- 1995-06-01 HU HU9603562A patent/HU220747B1/hu not_active IP Right Cessation
- 1995-06-01 CN CN95194672A patent/CN1156966A/zh active Pending
- 1995-06-01 AT AT95922160T patent/ATE233101T1/de not_active IP Right Cessation
- 1995-06-01 JP JP8503166A patent/JPH10501987A/ja active Pending
- 1995-06-01 EP EP95922160A patent/EP0768893B1/en not_active Expired - Lifetime
- 1995-06-01 WO PCT/US1995/006915 patent/WO1996000583A1/en active IP Right Grant
- 1995-06-06 ZA ZA954641A patent/ZA954641B/xx unknown
-
1996
- 1996-12-18 PL PL95317874A patent/PL180639B1/pl unknown
- 1996-12-18 NZ NZ288045A patent/NZ288045A/en unknown
- 1996-12-27 FI FI965224A patent/FI965224A/fi unknown
- 1996-12-27 NO NO965590A patent/NO965590L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1156966A (zh) | 1997-08-13 |
| WO1996000583A1 (en) | 1996-01-11 |
| CA2193365C (en) | 2007-04-03 |
| HU220747B1 (hu) | 2002-05-28 |
| NZ288045A (en) | 1998-08-26 |
| ES2191052T3 (es) | 2003-09-01 |
| EP0768893A1 (en) | 1997-04-23 |
| HU9603562D0 (en) | 1997-02-28 |
| MX9700229A (es) | 1997-04-30 |
| PL317874A1 (en) | 1997-04-28 |
| FI965224A0 (fi) | 1996-12-27 |
| CZ375296A3 (en) | 1997-08-13 |
| AU701973B2 (en) | 1999-02-11 |
| PL180639B1 (pl) | 2001-03-30 |
| ZA954641B (en) | 1996-01-26 |
| NO965590D0 (no) | 1996-12-27 |
| AU2694595A (en) | 1996-01-25 |
| US5866553A (en) | 1999-02-02 |
| HUT76446A (en) | 1997-09-29 |
| EP0768893B1 (en) | 2003-02-26 |
| IL113817A (en) | 2001-03-19 |
| SK164196A3 (en) | 1997-08-06 |
| ATE233101T1 (de) | 2003-03-15 |
| FI965224A (fi) | 1996-12-27 |
| IL113817A0 (en) | 1995-08-31 |
| DE69529748D1 (de) | 2003-04-03 |
| DE69529748T2 (de) | 2003-10-16 |
| JPH10501987A (ja) | 1998-02-24 |
| CA2193365A1 (en) | 1996-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU701973B2 (en) | Polynucleotide vaccine for papillomavirus | |
| RU2360001C2 (ru) | Оптимизированная экспрессия l1 hpv45 в дрожжах | |
| Lin et al. | Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product | |
| EP3031822A1 (en) | Cytomegalovirus antigens | |
| US10736954B2 (en) | L2 peptide immunogenicity | |
| JPH10510989A (ja) | ヒトパピローマウイルス抗原の変異体 | |
| WO1998023635A1 (en) | Novel promiscuous t helper cell epitopes | |
| EP0692028B1 (en) | Pharmaceuticals based on papillomaviruses | |
| CN113666990A (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| JP2002516291A (ja) | パピローマウイルス・ウイルス様粒子による経口免疫感作 | |
| KR101506979B1 (ko) | 전형적 돼지 콜레라 바이러스에 대한 키메릭 백신 항원 | |
| CN116284272B (zh) | 一种广谱抗牛科病毒性腹泻病毒的mRNA疫苗及其应用 | |
| AU708460B2 (en) | A polynucleotide herpes virus vaccine | |
| US20050118139A1 (en) | Vaccine using papilloma virus e proteins delivered by viral vector | |
| WO2021013071A1 (zh) | 人乳头瘤病毒多价免疫原性组合物 | |
| Qin et al. | Human papillomavirus type 16 E7 peptide38–61 linked with an immunoglobulin G fragment provides protective immunity in mice | |
| MXPA05003558A (es) | Vacuna de adn que codifica al menos dos proteinas tempranas no estructurales de papilomavirus. | |
| RU2173170C2 (ru) | Полинуклеотидная вакцина для вируса папилломы | |
| Deng et al. | The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro | |
| Kwak | Development of prophylactic human papillomavirus vaccines | |
| AU660954B2 (en) | Subunit papillomavirus vaccine and peptides for use therein | |
| CZ28899A3 (cs) | Polypeptidy použitelné jako imunoterapeutická činidla a způsoby přípravy polypeptidů | |
| Embers | Immunogenicity and Cellular Protein Associations of the Papillomavirus Minor Capsid Protein | |
| AU5013099A (en) | Papillomavirus vaccine | |
| NO176996B (no) | Fremgangsmåte for fremstilling av en farmasöytisk sammensetning for beskyttelse av felin leukemivirus (FeLV) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |